Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated.

Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia. a critical review of the literature / Busetto, Gian Maria; Del Giudice, Francesco; D'Agostino, Daniele; Romagnoli, Daniele; Minervini, Andrea; Rocco, Bernardo; Antonelli, Alessandro; Celia, Antonio; Schiavina, Riccardo; Cindolo, Luca; Chung, Benjamin I; Kim, Jae Heon; Maggi, Martina; Sciarra, Alessandro; De Berardinis, Ettore; Porreca, Angelo. - In: ARCHIVIO ITALIANO DI UROLOGIA ANDROLOGIA. - ISSN 1124-3562. - 91:4(2019), pp. 205-211. [10.4081/aiua.2019.4.205]

Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia. a critical review of the literature

Busetto, Gian Maria
;
Del Giudice, Francesco;Minervini, Andrea;Rocco, Bernardo;Antonelli, Alessandro;Celia, Antonio;Maggi, Martina;Sciarra, Alessandro;De Berardinis, Ettore;
2019

Abstract

Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated.
File allegati a questo prodotto
File Dimensione Formato  
Busetto_Efficacy-safety-finasteride_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 881.66 kB
Formato Adobe PDF
881.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1353948
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact